Glutathione — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 6 sources[1,2,3,4,5,6].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Related impurities in peptide medicines | Journal of Pharmaceutical and Biomedical Analysis | 2014 |
| 2 | Stability of protein pharmaceuticals: an update | Pharmaceutical Research | 2010 |
| 3 | General Chapter ⟨85⟩ Bacterial Endotoxins Test | United States Pharmacopeia — National Formulary (USP–NF) | 2024 |
| 4 | General Chapter ⟨71⟩ Sterility Tests | United States Pharmacopeia — National Formulary (USP–NF) | 2024 |
| 5 | ICH Q1A(R2) Stability Testing of New Drug Substances and Products | ICH Harmonised Tripartite Guideline | 2003 |
| 6 | Protein aggregation — pathways and influencing factors | International Journal of Pharmaceutics | 2010 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 5 | GSH-PD-PH2 · GSH-PD-PH2-ELDERLY · GSH-PD-PH2-OLE · GSH-PD-PH2-ADHERENCE · GSH-PD-PH2-BIOMARKER |
| Evidence syntheses | 0 | none |
| Comment periods | 1 | Draft monograph: Glutathione |
| Indication assessments | 3 | Cognition · Immune modulation · Ageing |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
- United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- United States Pharmacopeial Convention. General Chapter ⟨71⟩ Sterility Tests. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
- Wang W, Nema S, Teagarden D. Protein aggregation — pathways and influencing factors. International Journal of Pharmaceutics 2010;390(2):89–99. doi:10.1016/j.ijpharm.2010.02.025 · PMID 20188795
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.